Merck to acquire Pandion Therapeutics
KENILWORTH, N.J. — Merck and Pandion Therapeutics announced Thursday that the companies have entered into a definitive agreement, under which Merck, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash. This represents an
